問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Tri-Service General Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

更新時間:2023-09-19

詹德全
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

12Cases

2005-10-01 - 2006-12-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-09-01 - 2026-08-31

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-10-01 - 2027-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting13Sites

Terminated3Sites

2017-04-27 - 2018-12-31

Phase I

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
  • Condition/Disease

    Gastric Cancer/Esophageal Cancer/Gastro-esophageal Cancer

  • Test Drug

    Oraxol + Ramucirumab

Participate Sites
7Sites

Terminated6Sites

2022-09-01 - 2026-08-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2017-06-02 - 2020-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

2014-11-01 - 2022-02-28

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    nab-Paclitaxel

Participate Sites
6Sites

Terminated6Sites

2020-02-01 - 2026-02-01

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2016-12-01 - 2021-05-31

Phase I/II

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Treatment-Naïve (locally advanced) or Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
  • Condition/Disease

    Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

  • Test Drug

    Margetuximab

Participate Sites
3Sites

Terminated3Sites

趙毅
Taipei Veterans General Hospital

Digestive System Department

2018-06-01 - 2021-02-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 2